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Age-related penetrance of the 
C9orf72 repeat expansion
Natalie A. Murphy1, Karissa C. Arthur2, Pentti J. Tienari3,4, Henry Houlden5, Adriano Chiò6 & 
Bryan J. Traynor1,7
A pathogenic hexanucleotide repeat expansion within the C9orf72 gene has been identified as 
the major cause of two neurodegenerative syndromes, amyotrophic lateral sclerosis (ALS) and 
frontotemporal dementia (FTD). This mutation is known to have incomplete penetrance, with some 
patients developing disease in their twenties and a small portion of carriers surviving to their ninth 
decade without developing symptoms. Describing penetrance by age among C9orf72 carriers and 
identifying parameters that alter onset age are essential to better understanding this locus and to 
enhance predictive counseling. To do so, data from 1,170 individuals were used to model penetrance. 
Our analysis showed that the penetrance was incomplete and age-dependent. Additionally, familial 
and sporadic penetrance did not significantly differ from one another; ALS cases exhibited earlier age 
of onset than FTD cases; and individuals with spinal-onset exhibited earlier age of onset than those 
with bulbar-onset. The older age of onset among female cases in general, and among female bulbar-
onset cases in particular, was the most striking finding, and there may be an environmental, lifestyle, 
or hormonal factor that is influencing these penetrance patterns. These results will have important 
applications for future clinical research, the identification of disease modifiers, and genetic counseling.
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by rapidly progressive paral-
ysis and death due to respiratory failure, typically within 2–4 years of onset. Approximately 7,000 Americans 
die annually from ALS, making it the most common adult-onset motor neuron disease1. The number of ALS 
cases across the globe will increase to nearly 400,000 in 2040, predominantly due to aging of the population2. 
Furthermore, the annual cost per patient with ALS, as well as the burden placed on family and caregivers, is 
among the highest for any neurological disease3.
The discovery of the pathogenic hexanucleotide repeat expansion in C9orf72 was a major advance in our 
understanding of the etiology of ALS and frontotemporal dementia (FTD)4, 5. The C9orf72 repeat expansion 
accounts for 1 in 10 of every ALS case among European-ancestry populations5, 6. This represents the first time 
that a large non-coding repeat expansion has been implicated in either of these neurodegenerative diseases. There 
is a growing sense of optimism that antisense oligonucleotide therapy or a small molecule therapeutic may be 
effective in slowing progression in patients carrying the expansion, and such gene therapy trials may commence 
enrollment in the near future7.
The variable phenotype associated with this mutation complicates these clinical trial efforts, especially future 
studies testing the ability of therapies to delay disease onset among asymptomatic carriers. For example, the age 
of symptom onset fluctuates widely among mutation carries, ranging from 40 to 90 years of age. Some carriers 
do not manifest disease even in their ninth decade of life, indicating that penetrance of this mutation is incom-
plete. We previously published age-related estimates of C9orf72 penetrance based on a relatively small cohort of 
carriers6. Here, we aim to improve on these estimates by incorporating a larger cohort. We also investigate which 
clinical and demographic factors influence penetrance. A better understanding of the age-related penetrance 
of the C9orf72 repeat expansion will help in clinical trial design, and ultimately in determining at what stage to 
initiate neuroprotective therapy, should it become available in the future.
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Results
Penetrance is the proportion of individuals carrying a mutated gene that also express the affected phenotype8. 
Age-related penetrance indicates that the expression of the phenotype in mutant-gene carriers is dependent upon 
the individual’s age. To gather the necessary raw data to calculate penetrance of the C9orf72 mutation, we per-
formed a literature search in PubMed.
Our literature search identified 37,991 patients diagnosed with neurodegenerative disease who were screened 
for the presence of the C9orf72 repeat expansion. Of these, 3,457 carried the pathogenic mutation, representing 
a carrier rate of 9.1% among cases. After excluding those with insufficient data, 1,147 cases of repeat expansion 
were available for analysis based on a cohort of 13,672 (8.4%). The majority of these cases presented with ALS 
(n = 735, 64.0% of the total). Out of 36,420 total control samples that were reported in the literature, 40 had the 
repeat expansion (0.1%). This number was reduced to 23 after excluding those with unavailable age of onset data 
(0.06%). In summary, data from 1,170 individuals was available for analysis. The complete data set for the 1,170 
individuals can be found as Supplemental Table S2, and the gender, site of onset, and age at onset distributions of 
this cohort are shown in Fig. 1.
Our data showed that median age at symptom onset among carriers of the C9orf72 repeat expansion was 58.0 
years of age (95% confidence interval: 57.0 to 59.0; see black curve in Fig. 2). The youngest reported age at symp-
tom onset was 25 years among a man who presented with ALS. Penetrance was cumulatively nearly complete 
(99.5%) by 83 years of age. More than half (n = 13, 56.5%) of the neurologically normal individuals carrying the 
repeat expansion were younger than the median age of onset.
The selection of data based on random cohorts of screened patients and controls may be subject to ascertain-
ment bias compared to estimates based on selection within families. This bias arises from a decreased enroll-
ment among asymptomatic carriers. To model this possibility, we artificially increased our percentage of control 
Figure 1. Relationship between gender and site of onset in C9orf72 repeat expansion carriers. Donut chart 
showing the site of symptom onset and age at onset among male and female C9orf72 carriers. Inner layer shows 
the proportion of males (52.6%) and females (47.4%) in the cohort. The middle layer shows the site of onset 
within males and females. The outer histogram layer shows the age distribution within each subset. The y-axis 
of this outer histogram represents the number of patients at each age, whereas the x-axis represents age at 
symptom onset ranging from 25 to 83 years of age. The graph was created using Circos (version 0.67, available at 
www.circos.ca) and FusionCharts (www.jsfiddle.net/fusioncharts/J7svz).
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subjects from 2.0% to 20% by adding an additional 293 asymptomatic subjects and randomly assigning them ages 
at screening that ranged from the youngest to the oldest ages at onset observed among our cases (25 to 91 years 
of age). The modeled data and the actual data had a statistically significant difference (median age of symptom 
onset = 60.0 years of age; Log-rank test = 66.2, p-value = 4.4 × 10−16; see red curve in Fig. 2). Notably, penetrance 
at older ages was lower when the control rate was increased (90.9% at age 83). More data on very elderly asympto-
matic carriers is needed to precisely estimate the cumulative penetrance at old age. We used our original data with 
a 2.0% control rate in our subsequent analysis of penetrance, keeping in mind that the cumulative penetrance in 
the oldest age-groups may be less accurate.
We next explored clinical and demographic factors that may influence age-related penetrance among C9orf72 
carriers. We observed that familial and sporadic C9orf72 cases had nearly identical penetrance by age (median age 
of onset among familial C9orf72 cases = 57.0 years of age, 95% confidence interval (CI): 56.0–58.0; median age of 
onset among sporadic C9orf72 cases = 58.0, 95% CI: 58.0–59.0; Log-rank test = 3.2, p-value = 0.07; see Fig. 3A).
Penetrance by age was modestly higher among C9orf72 carriers presenting with pure ALS (median age 
of onset = 57.0 years of age, 95% CI: 56.0–58.0) compared to those presenting with pure FTD (median age of 
onset = 58.0 years of age, 95% CI: 57.0–60.0; Log-rank test = 4.4, p-value = 0.04; see Fig. 3B).
Male carriers of C9orf72 had a greater likelihood of developing disease at a younger age than females (see 
Fig. 3C). Though this difference was relatively small (2-year difference in median survival), it was observed 
over nearly the entire range of age at onset and was statistically significant (median age of onset in males = 57.0 
years of age, 95% CI: 56.0–58.0; median age of onset in females = 59.0, 95% CI: 58.0–60.0; Log-rank test = 5.1, 
p-value = 0.02).
Higher penetrance by age was also observed among cases with spinal-onset disease (median age of 
onset = 57.0 years of age, 95% CI: 56.0–58.0) compared to bulbar-onset (median age of onset = 59.0 years of 
age, 95% CI: 57.0–60.0; Log-rank test = 5.8, p-value = 0.02; see Fig. 3D). Intriguingly, density plots displaying 
the likelihood of developing disease at a given age indicated that this difference was driven by the older age of 
bulbar-onset disease among women compared to men (median age of disease onset among women = 60.0 years 
of age, 95% CI: 58.0–61.0; median age among men = 57.0, 95% CI: 56.0–59.0; see Fig. 4A–C). In contrast, there 
was no difference in age at onset of spinal-onset disease between genders (see Fig. 4D).
Discussion
In this paper, we modeled the penetrance of the C9orf72 hexanucleotide repeat expansion based on a large cohort 
drawn from published literature. We found that the penetrance of C9orf72 repeat expansion exhibits incom-
plete, age-dependent penetrance, which confirms our previous findings and those of other groups6, 9. This more 
complete picture of C9orf72 repeat expansion age-dependent penetrance will aid in the design and execution of 
clinical trials, and may be important – hopefully – in the future for decisions related to timing and administration 
of preventative therapy.
Our data show that family history of disease does not affect penetrance of C9orf72. This observation suggests 
that many sporadic cases are likely to be familial patients in disguise10. Genetic data showing that familial and 
sporadic cases of the C9orf72 repeat expansion share the same haplotype also support this notion6, 11, 12. There are 
many reasons why familial disease might appear sporadic, including an incomplete family history and the death 
of previous generations before their disease development was evident. It is interesting to note that life expectancy 
in the United States did not reach 58, the median age at onset for C9orf72 penetrance, until 193013. This means 
that a member of a previous generation had an equal chance of dying from another disease, a phenomenen known 
as Gompertzian inter-disease competition14.
We also observed a slightly higher age-related penetrance among ALS compared to FTD cases. This phenom-
enon was mostly driven by individuals under the age of 58 years of age, whereas penetrance was identical above 
this age. The cause of this younger age of onset among ALS cases is not clear. One possibility is that the prodromal 
phase may be relatively short in ALS compared to FTD, reflecting the smaller baseline pool of motor neurons that 
Figure 2. Age-related penetrance of the pathogenic C9orf72 repeat expansion. The black curve shows age-
related penetrance of 1,147 symptomatic patients and 23 asymptomatic individuals carrying the C9orf72 repeat 
expansion. The shading represents the 95% confidence interval and censored individuals (i.e. asymptomatic) are 
indicated by crosses. The red curve represents model data in which the proportion of asymptomatic individuals 
is artificially increased to 20% (n = 316).
www.nature.com/scientificreports/
4Scientific RepoRts | 7: 2116  | DOI:10.1038/s41598-017-02364-1
must be destroyed to give rise to symptoms. It is also possible that the diagnosis of FTD is delayed as cognitive 
symptoms are more subtle than motor symptoms, or because of a more complex network of compensatory mech-
anisms may exist to delay overt symptoms. Alternatively, there may be an environmental, lifestyle, or hormonal 
factor that is driving the earlier onset of ALS cases, or that is acting in a protective manner among FTD cases15, 16.
The most pertinent finding regarding C9orf72 penetrance was the older age of disease onset among female 
cases and among bulbar-onset cases. It has long been recognized that bulbar-onset ALS is more common among 
elderly females17, and these findings seem to point to a linkage between an individual’s sex and site of onset (see 
Fig. 1)15, 18. A hormonal or X-linked factor influencing disease type and the site of onset has been postulated, since 
women who develop ALS often have a later menarche and earlier menopause than controls15, 19.
We have examined the age-related penetrance associated with the C9orf72 repeat expansion in a large cohort. 
It is important, however, to note the limitations of our approach. First, the relatively small number of cases 
(hundreds, rather than thousands) involved in our subgroup analysis limits power to detect real differences. 
Nevertheless, it is encouraging that the overall results from our current analysis are remarkably similar to what 
we previously reported6, 20. Second, an important question that remains is what is the true cumulative penetrance 
by the ninth decade of life. Our modeling indicates that disease penetrance associated with the C9orf72 repeat 
expansion continues to rise beyond the seventh decade of life. For this reason, modeling of penetrance based on 
asymptomatic members within kindreds is likely to be inaccurate, as these individuals are younger and have not 
yet had an opportunity to develop disease and provide definitive information. Instead, analysis of a large cohort 
of elderly asymptomatic carriers will be required to definitively settle this issue.
A clinical trial of anti-sense oligonucleotide silencing the C9orf72 repeat expansion is likely to commence 
enrollment soon7. If this trial is successful in slowing disease progression in patients, then an obvious evolution 
will be to determine if therapeutic intervention in asymptomatic C9orf72 carriers can delay or even prevent dis-
ease onset. Similar prevention clinical trials are already underway in other neurodegenerative diseases (for exam-
ple, Crenezumab in PSEN1 mutation carriers, www.clinicaltrials.gov/ct2/show/NCT01998841). Exciting as this 
prospect may be, the variable age at onset among C9orf72 repeat expansion carriers poses an obstacle to such tri-
als, especially given the lack of a robust biomarker that can predict disease onset. Our data on C9orf72 penetrance 
help to bridge this gap in our knowledge, and may be a critical element in the design of preventative clinical trials.
In conclusion, while familial and sporadic status does not influence age-related penetrance of C9orf72, pen-
etrance by age does differ based on an individual’s sex, site of symptom onset, and the nature of the presenting 
neurological syndrome. These results will have important use for clinical research and genetic counseling for 
Figure 3. Age-related penetrance of the pathogenic C9orf72 repeat expansion classified by subtype. (A) Age-
related penetrance based on familial (n = 555) and sporadic (n = 544) status; (B) age-related penetrance curves 
based on ALS (n = 734) and FTD (n = 303) clinical phenotype; (C) age-related penetrance curves comparing 
male (n = 612) and female (n = 543) cases of ALS and FTD; (D) age-related penetrance curves among ALS 
patients based on bulbar (n = 270) or spinal (n = 481) site of symptom onset. The shading represents the 95% 
confidence interval and censored individuals (i.e. asymptomatic) are indicated by crosses.
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those with family history of disease. The next step is to determine the sources behind these variations, which may 
be genetic, environmental, or lifestyle factors.
Materials and Methods
Literature review. To gather the necessary raw data to calculate penetrance of the C9orf72 mutation, we 
performed a literature search in PubMed using the term “C9orf72” combined with the MeSH terms “amyotrophic 
lateral sclerosis,” OR “motor neuron disease,” OR “dementia, frontotemporal”, OR “degeneration, frontotemporal 
lobar,” as well as specifying “humans.” The search was conducted in May 2016, and was limited to publications 
dating 2011 and later.
The literature search identified 71 articles reporting on a series of patients and neurologically normal 
individuals who were screened for presence of the C9orf72 repeat expansion. Of these, 40 articles contained 
individual-level information on the age of symptom onset or age of screening among asymptomatic carriers. The 
entire list of publications can be found as Supplementary Information. The age and sex of those individuals with 
the repeat expansion was extracted from these publications, along with the country of origin, disease diagnosis, 
site of disease onset, and sporadic/familial status, if available.
Cataloging of extracted data. The individual’s diagnosis could be categorized into one of nine options: 
ALS (n = 735), ALS-FTD (n = 76), FTD (n = 303), FTD-ALS (n = 20), Parkinson’s disease (n = 2), Alzheimer’s 
disease (n = 1), corticobasal syndrome (n = 1), olivopontocerebellar degeneration (n = 1), and neurologically 
normal (control subject, n = 23). As 96.9% of the patient diagnoses were either ALS or FTD, we focused on those 
two neurodegenerative diseases for our modeling of penetrance. The site of onset fell into one of four catego-
ries: bulbar, spinal, generalized, or cognitive. Disease pattern was classified as familial or sporadic based on the 
presence or absence of a family history of ALS or FTD. Data was available from 27 locations (see Supplemental 
Table S1 for full breakdown).
Statistical analysis. To calculate age-related penetrance, we generated Kaplan-Meier plots in R statistical 
software (version 3.3.1) using the Prodlim (version 1.5.1) and Survival (version 2.38) packages9, 21, 22. Age at symp-
tom onset was used as event time among affected individuals and age at screening and/or sample collection 
was used as censor time for asymptomatic carriers. Comparison between groups was performed using Log-rank 
tests within the Survival package. To model unaffected carriers that may not have been captured, we added 293 
Figure 4. Density plots of age of onset among pathogenic C9orf72 repeat expansion carriers. Density plot 
showing age of onset frequency distribution (A) among male (n = 393) and female (n = 357) ALS cases; (B) 
bulbar-onset (n = 256) and spinal-onset ALS cases (n = 481); (C) bulbar-onset male (n = 111) and bulbar-onset 
female (n = 111) ALS cases; (D) spinal-onset male (n = 273) and spinal-onset female (n = 208) cases. Shaded 
area represents differences between compared subgroups, and the dotted vertical line indicates median age of 
onset in the overall cohort (58.0 years of age).
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controls using the sample function in R to increase the portion of unaffected carriers in our cohort to 20% and 
randomly assigned them ages between 25 and 91 years. We used density estimation to generate posterior proba-
bilities of developing symptoms based on age, gender, and site of symptom onset.
Ethical approval. The analyses presented in this study were based on published literature, and the study was 
approved by the institutional review board of the National Institutes of Health (protocol number 03-AG-N329).
Data availability. The complete data set used for this study, and the R programming code used to analyze 
these data are freely available at https://github.com/nam10/C9_Penetrance.
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